Intranasal Brain Cancer Treatment – NeOnc Technologies is revolutionizing brain cancer treatment

Sep 8, 2025

Investors and biotech innovators, discover how NeOnc Technologies is revolutionizing brain cancer treatment with intranasal drug delivery that bypasses the blood-brain barrier. Janet Alvarez interviews Amir F. Heshmatpour, Executive Chairman and President of NeOnc, to discuss:

A groundbreaking delivery method for brain cancer drugs via the nose

Phase 1 and Phase 2 clinical trials currently underway across 10+ hospitals

Expansion into India and the Middle East, including a $50M Quasar partnership

Inclusion in the Russell 2000 and recent Nasdaq listing

Vision for FDA-approved standard-of-care cancer treatments within 3–5 years

With 179 patents and cutting-edge acquisitions in AI, quantum modeling, and 3D printing, NeOnc is positioning itself as a major player in oncology innovation.

➡️ Learn why NeOnc (Nasdaq: NENC) may be undervalued and how it’s disrupting the biotech space.

📺 Watch now for exclusive insights from the frontlines of cancer research and investment strategy.

📌 Tags

#Biotech #BrainCancer #NasdaqStocks #NeOnc #IntranasalTherapy #NewToTheStreet #CancerResearch #PharmaInnovation #HealthcareInvesting #Russell2000 #Oncology #FDAApproval #BiotechStocks #ClinicalTrials #AIinHealthcare #USCResearch #Neuroscience #InvestInBiotech #StartupStocks